LDHA
L-lactate dehydrogenase A chain
As of the edition of 20 October 2026, LDHA (L-lactate dehydrogenase A chain, UniProt P00338) has 2 drugs tested at it and 1 company on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00338
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 46
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal; Nutrition and metabolism
- Registered trials of its drugs
- 7
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nedosiran sodium | Marketed | Phase 3 | Ends 2038 |
| Nedosiran | Marketed | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Novo Nordisk | Route B |
The other 0 companies at LDHA
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at LDHA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.